Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - octreotide acetate 33.6mg equivalent to octreotide 30 mg;   - powder for injection - 30 mg - active: octreotide acetate 33.6mg equivalent to octreotide 30 mg   excipient: mannitol polyglactin carmellose sodium mannitol poloxamer water for injection carmellose sodium mannitol water for injection - treatment of patients with acromegaly: · in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours: · carcinoid tumours with features of the carcinoid syndrome. · vipomas · glucagonomas · gastrinomas/zollinger-ellison syndrome · insulinomas, for pre-operative control of hypoglycaemia and for maintenance therapy. · grfomas

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - deferoxamine mesilate 500mg - powder for injection - 500 mg - active: deferoxamine mesilate 500mg - monotherapy iron chelation treatment for chronic iron overload, e.g. · transfusional haemosiderosis, as seen in thalassaemia major, sideroblastic anaemia, autoimmune haemolytic anaemia, and other chronic anaemias. · idiopathic (primary) haemochromatosis in patients in whom concomitant disorders (e.g. severe anaemia, cardiac disease, hypoproteinaemia) preclude phlebotomy. · iron overload associated with porphyria cutanea tarda in patients unable to tolerate phlebotomy.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine 18mg;  ;   - transdermal patch - 9.5 mg/24h - active: rivastigmine 18mg     excipient: dimeticone dl-alpha tocopherol acrylic pressure sensitive adhesive silicone pressure sensitive adhesive backing film 10 cm square release liner 20.25 cm square poly(butyl methacrylate-co-methyl methacrylate) - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine 27mg;  ;   - transdermal patch - 13.3 mg/24h - active: rivastigmine 27mg     excipient: dimeticone dl-alpha tocopherol acrylic pressure sensitive adhesive silicone pressure sensitive adhesive backing film 15 cm square release liner 30.375 cm square poly(butyl methacrylate-co-methyl methacrylate) - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine 36mg;  ;   - transdermal patch - 17.4 mg/24h - active: rivastigmine 36mg     excipient: dimeticone dl-alpha tocopherol acrylic pressure sensitive adhesive silicone pressure sensitive adhesive backing film 20 cm square release liner 40.5 cm square poly(butyl methacrylate-co-methyl methacrylate) - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine 9mg;  ;   - transdermal patch - 4.6 mg/24h - active: rivastigmine 9mg     excipient: dimeticone dl-alpha tocopherol acrylic pressure sensitive adhesive silicone pressure sensitive adhesive backing film 5 cm square release liner 10.125 cm square poly(butyl methacrylate-co-methyl methacrylate) - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - octreotide acetate 0.056 mg/ml equivalent to 0.05 mg/ml octreotide base - solution for injection - 0.05 mg/ml - active: octreotide acetate 0.056 mg/ml equivalent to 0.05 mg/ml octreotide base excipient: lactic acid mannitol sodium bicarbonate water for injection

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - octreotide acetate 0.112 mg/ml equivalent to 0.1 mg/ml octreotide base - solution for injection - 0.1 mg/ml - active: octreotide acetate 0.112 mg/ml equivalent to 0.1 mg/ml octreotide base excipient: lactic acid mannitol sodium bicarbonate water for injection

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - octreotide acetate 0.56 mg/ml equivalent to 0.5 mg/ml octreotide base - solution for injection - 0.5 mg/ml - active: octreotide acetate 0.56 mg/ml equivalent to 0.5 mg/ml octreotide base excipient: lactic acid mannitol sodium bicarbonate water for injection

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - deferasirox 125mg;  ;   - dispersible tablet - 125 mg - active: deferasirox 125mg     excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium laurilsulfate - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and paediatric patients (aged 2 years and over).